Advertisement

Canadian Journal of Public Health

, Volume 95, Issue 4, pp 249–255 | Cite as

Pediatric Tuberculosis in Alberta First Nations (1991–2000)

Outbreaks and the Protective Effect of Bacille Calmette-Guérin (BCG) Vaccine
  • Richard LongEmail author
  • Denise Whittaker
  • Krista Russell
  • Dennis Kunimoto
  • Robert Reid
  • Anne Fanning
  • Ewa Nobert
  • Lyle Melenka
  • Wadieh Yacoub
  • Ravi Bhargava
Article
  • 9 Downloads

Abstract

Background: The tuberculosis control strategy of vaccinating First Nations newborns with BCG (bacille Calmette-Guérin) is currently undergoing re-evaluation in Canada. Review of recent pediatric tuberculosis morbidity could inform this re-evaluation.

Methods: Potential source cases and pediatric cases of tuberculosis from Alberta First Nations were identified over the 10 years 1991–2000. The distribution of pediatric disease was described. The effect of BCG on tuberculosis morbidity in two large outbreaks was determined.

Results: A total of 57 potential source cases and 41 pediatric cases of tuberculosis were reported from 17 (41.5%) and 8 (19.5%) of the 41 on-reserve First Nation Community Health Centres, respectively. Three outbreaks traceable to three source cases accounted for 34 (18, 3, and 13, respectively) of the 41 (82.9%) pediatric cases. Each outbreak was spatially and temporally separate from the other. Each outbreak strain of Mycobacterium tuberculosis had a unique DNA fingerprint. In the largest outbreaks, disease-to-infection ratios (secondary case rates) were higher in newly infected unvaccinated versus vaccinated close pediatric contacts (12/13 [92.3%] versus 7/15 [46.7%], p=0.02), but the infection rate was almost certainly falsely high in the BCG vaccinated. One unvaccinated child had a brain tuberculoma in addition to primary pulmonary tuberculosis.

Conclusion: For most Alberta First Nations communities, the spatial and temporal distribution of disease, and the meager impact on morbidity, challenge the rationale for continued use of BCG.

Résumé

Contexte: On réévalue actuellement au Canada la stratégie de contrôle de la tuberculose qui consiste à vacciner les nouveau-nés des Premières nations par le BCG (bacille Calmette-Guérin). Un examen de la morbidité récente due à la tuberculose infantile pourrait étayer cette réévaluation.

Méthode: Nous avons relevé les cas sources potentiels et les cas de tuberculose infantile chez les Premières nations de l’Alberta pendant la décennie 1991–2000, puis décrit la répartition de la maladie infantile. Nous avons ensuite déterminé l’effet du BCG sur la morbidité due à la tuberculose lors de deux grandes poussées épidémiques.

Résultats: En tout, 57 cas sources potentiels ont été déclarés dans 17 des 41 centres de santé communautaire des Premières nations dans les réserves (41,5 %), et 41 cas de tuberculose infantile ont été déclarés dans 8 des 41 centres (19,5 %). Trois poussées épidémiques dont a pu retracer les trois cas sources ont été à l’origine de 34 (18, 3 et 13, respectivement) des 41 cas de tuberculose infantile (82,9 %). Chaque poussée était distincte des autres dans l’espace et dans le temps. Chaque souche épidémique de Mycobacterium tuberculosis avait sa propre empreinte génétique. Lors des plus grosses poussées, les rapports maladie/infection (les taux d’attaque secondaire) étaient plus élevés chez les enfants non vaccinés nouvellement infectés en contact étroit avec des personnes atteintes que chez les enfants vaccinés (12/13 [92,3 %] contre 7/15 [46,7 %], p=0,02), mais le taux d’infection était presque certainement faussement élevé chez les enfants vaccinés par le BCG. L’un des enfants non vaccinés présentait un tuberculome des méninges en plus d’une tuberculose pulmonaire primaire.

Conclusion: Dans la plupart des communautés des Premières nations de l’Alberta, la répartition de la maladie dans le temps et dans l’espace et le maigre effet du BCG sur la morbidité mettent en doute le bien-fondé de continuer à administrer le vaccin.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Long R, Sutherland K, Kunimoto D, Cowie R, Manfreda J. The epidemiology of tuberculosis among foreign-born persons in Alberta, Canada, 1989-1998: Identification of high risk groups. Int J Tuberc Lung Dis 2002;6:615–21.PubMedGoogle Scholar
  2. 2.
    Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analysis of the published literature. Pediatrics 1995;96:29–35.PubMedGoogle Scholar
  3. 3.
    Fine PEM. BCG vaccines and vaccination. In: Reichman LB, Hershfield ES (Eds.), Tuberculosis: A Comprehensive International Approach, 2nd Edition. Lung Biology in Health and Disease, vol 144. New York, NY: Marcel Dekker, Inc, 2000;503–22.Google Scholar
  4. 4.
    Scheifele D, Law B, Jadavji T on behalf of IMPACT. Disseminated bacille Calmette-Guerin infection: three recent Canadian cases. CCDR;24-9:1–5.Google Scholar
  5. 5.
    Cunningham JA, Kellner JD, Bridge PJ, Trevenen CL, McLeod DR, Davies HD. Disseminated bacille Calmette-Guerin infection in an infant with a novel deletion in the interfer-on-gamma receptor gene. Int J Tuberc Lung Dis 2000;4:791–94.PubMedGoogle Scholar
  6. 6.
    International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guérin (BCG) in countries with a low prevalence of tuberculosis. Tuberc Lung Dis 1994;75:179–81.CrossRefGoogle Scholar
  7. 7.
    Houston S, Fanning A, Soskolne CL, Fraser N. The effectiveness of bacillus Calmette-Guerin (BCG) vaccination against tuberculosis. Am J Epidemiol 1990;131:340–48.CrossRefGoogle Scholar
  8. 8.
    Menzies D, Pourier L. Diagnosis of tuberculosis infection and disease. In: Long R (Ed.), The Canadian Tuberculosis Standards, 5th edition. Ottawa: Health Canada and the Canadian Lung Association, 2000;45–65.Google Scholar
  9. 9.
    Leung AN, Muller NL, Pineda PR, FitzGerald JM. Primary tuberculosis in childhood: Radiologic manifestations. Radiology 1992;182:87–91.CrossRefGoogle Scholar
  10. 10.
    Tannenbaum TN, Fanning A. Contact follow-up and outbreak management in tuberculosis control. In: Long R (Ed.), The Canadian Tuberculosis Standards, 5th edition. Ottawa: Health Canada and the Canadian Lung Association, 2000;175–86.Google Scholar
  11. 11.
    Long R, Bochar K, Chomyc S, Talbot J, Barrie J, Kunimoto D. The relative versus absolute non-contagiousness of respiratory tuberculosis on treatment. Infect Control Hosp Epidemiol 2003;24:831–38.CrossRefGoogle Scholar
  12. 12.
    Falk A, O’Connor JB, Pratt PC, Webb WR, Wier JA, Wolinsky E. Classification of pulmonary tuberculosis. In: Diagnostic Standards and Classification of Tuberculosis, 12th edition. National Tuberculosis and Respiratory Disease Association, New York, 1969;68.Google Scholar
  13. 13.
    Ferguson RG, Simes AB. BCG vaccination of infants in Saskatchewan. Tubercle 1949;30:5–11.CrossRefGoogle Scholar
  14. 14.
    Young TK, Hershfield ES. A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians. Am J Public Health 1986;76:783–86.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fayers PM, Barnett GD. The risk of tuberculous infection in Saskatchewan. Bull Int Union Tuberc Lung Dis 1975;50:62–69.Google Scholar
  16. 16.
    Young TK, Mirdad S. Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. Tuberc Lung Dis 1992;73:94–100.CrossRefGoogle Scholar
  17. 17.
    Comstock G. Frost revisited: The modern epidemiology of tuberculosis. Am J Epidemiol 1975;101:363–82.CrossRefGoogle Scholar
  18. 18.
    Sutherland I. The epidemiology of tuberculosis - is prevention better than cure. Bull Int Union Tuberc 1981;56:127–34.Google Scholar
  19. 19.
    Sutherland I, Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 1979;60:225–31.CrossRefGoogle Scholar
  20. 20.
    Sterne JAC, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200–7.PubMedGoogle Scholar
  21. 21.
    Styblo K, Meijer J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976;57:17–43.CrossRefGoogle Scholar
  22. 22.
    Porth FJ. Tuberculosis control among Indians in Saskatchewan. Can J Public Health 1968;59:111–14.Google Scholar
  23. 23.
    FitzGerald JM, Fanning A, Hoeppner V, Hershfield E, Kunimoto D, and the Canadian Molecular Epidemiology of TB Study Group. The molecular epidemiology of tuberculosis in western Canada. Int J Tuberc Lung Dis 2003;7:132–38.PubMedGoogle Scholar
  24. 24.
    Sharma MK, Al-Azem A, Wolfe J, Hershfield E, Kabani A. Identification of a predominant isolate of Mycobacterium tuberculosis using molecular epidemiology tools and in vitro cytokine responses. BMC Infect Dis. http://www.biomedcentral.com/1471-2334/3/3.
  25. 25.
    FitzGerald JM. A preliminary report of three cluster outbreaks of tuberculosis in British Columbia. Can Commun Dis Rep;20-1:1–3.Google Scholar
  26. 26.
    FitzGerald JM, Black WA, Kunimoto D. Evaluation of non-HIV-related, drug-sensitive cluster outbreaks of tuberculosis with PCR-based DNA fingerprinting. Can Respir J 1996;3:317–21.CrossRefGoogle Scholar
  27. 27.
    Grzybowski S, Allen EA. The challenge of tuberculosis in decline. Am Rev Respir Dis 1964;90:707–20.PubMedGoogle Scholar
  28. 28.
    Starke JR. Modern approach to the diagnosis and treatment of tuberculosis in children. Pediatr Clin North Am 1988;35:441–64.CrossRefGoogle Scholar
  29. 29.
    Lincoln EM. Epidemics of tuberculosis. Adv Tuberc Res 1965;14:157–201.Google Scholar
  30. 30.
    Raffalli J, Sepkowitz KA, Armstrong D. Community based outbreaks of tuberculosis. Arch Intern Med 1996;156:1053–60.CrossRefGoogle Scholar
  31. 31.
    Curtis AB, Ridzon R, Vogel R, McDonough S, Hargraves S, Ferry J, et al. Extensive transmission of Mycobacterium tuberculosis from a child. N Engl J Med 1999;341:1491–95.CrossRefGoogle Scholar
  32. 32.
    Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954;69:724–32.PubMedGoogle Scholar
  33. 33.
    Gryzbowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Report #3 of TSRU. Bull Int Union Tuberc 1975;50:90–106.Google Scholar
  34. 34.
    Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: The effects of chemotherapy. Tubercle 1976;57:275–99.CrossRefGoogle Scholar
  35. 35.
    Rose CE Jr, Zerbe GO, Lantz SO, Bailey WC. Establishing priority during investigation of tuberculosis contacts. Am Rev Respir Dis 1979;119:603–9.PubMedGoogle Scholar
  36. 36.
    Sultan L, Nyka W, Mills C, O’Grady F, Wells W, Riley R. Tuberculosis disseminators: A study of the variable aerial infectivity of tuberculosis patients. Am Rev Respir Dis 1960;82:358–69.PubMedGoogle Scholar
  37. 37.
    Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: A general review. Adv Tuberc Res 1970;17:28–106.Google Scholar
  38. 38.
    Miller FJW, Seale RME, Taylor MD. Tuberculosis in Children. Boston, MA: Little Brown, 1963.Google Scholar
  39. 39.
    Heimbeck J. Incidence of tuberculosis in young adult women, with special reference to employment. Br J Tubercle 1938;32:154–66.CrossRefGoogle Scholar
  40. 40.
    Badger TL, Ayvasian LF. Tuberculosis in nurses: Clinical observations on its pathogenesis as seen in a fifteen year follow-up of 745 nurses. Am Rev Tuberc 1949;60:305–31.PubMedGoogle Scholar
  41. 41.
    Daniels M. Primary tuberculosis infection in nurses: Manifestations and prognosis. Lancet 1944;244:165–70.CrossRefGoogle Scholar
  42. 42.
    Karns JR. Tuberculin sensitivity and tuberculosis in nursing and medical students. Dis Chest 1961;40:291–301.CrossRefGoogle Scholar
  43. 43.
    Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculous infection and tuberculous disease. Arch Environ Health 1971;22:106–12.CrossRefGoogle Scholar
  44. 44.
    Comstock GW, Palmer CE. Long term results of BCG vaccination in the southern United States. Am Rev Respir Dis 1966;93:171–83.PubMedGoogle Scholar
  45. 45.
    Greenwood CMT, Fujiwara TM, Boothroid LJ, Miller MA, Frappier D, Fanning EA, et al. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am J Hum Genet 2000;67:405–16.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Mah MW, Fanning EA. An epidemic of primary tuberculosis in a Canadian Aboriginal community. Can J Infect Dis 1991;2:133–41.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Davies JW. Epidemics of tuberculosis in Canada in the sixties. CMAJ 1976;96:1156–60.Google Scholar
  48. 48.
    Rideout VK, Hiltz JE. An epidemic of tuberculosis in a rural high school in 1967. Can J Public Health 1969;60:22–28.PubMedGoogle Scholar
  49. 49.
    Arneil AS, Battershill J. A mini-epidemic of tuberculosis in the Upper Fraser Valley Health Unit. Can J Public Health 1973;64:497–99.PubMedGoogle Scholar
  50. 50.
    Enarson DA, Gryzbowski S. Incidence of active tuberculosis in the native population of Canada. CMAJ 1986;134:1149–52.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Clark M, Riben P, Nowgesic E. The association of housing density, isolation and tuberculosis in Canadian First Nations communities. Int J Epidemiol 2002;31:940–45.CrossRefGoogle Scholar
  52. 52.
    Gaudette LA, Ellis E. Tuberculosis in Canada: A focal disease requiring distinct control strategies for different groups. Tuberc Lung Dis 1993;74:244–53.CrossRefGoogle Scholar
  53. 53.
    Lifschitz M. The value of the tuberculin skin test as a screening tool for tuberculosis among BCG-vaccinated children. Pediatrics 1965;36:624–27.PubMedGoogle Scholar
  54. 54.
    Karalliede S, Katugha LP, Uragoda CG. The tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987;68:33–38.CrossRefGoogle Scholar
  55. 55.
    Menzies R, Vissandjee B. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992;145:190–98.CrossRefGoogle Scholar
  56. 56.
    Sepulveda R, Burr C, Ferrer X, Sorensen R. Booster effect of tuberculin testing in healthy 6 year-old children vaccinated with bacillus Calmette-Guérin at birth in Santiago, Chile. Pediatr Infect Dis J 1988;7:578–81.CrossRefGoogle Scholar
  57. 57.
    Sepulveda R, Ferrer X, Latrach C, Sorensen R. The influence of Calmette-Guérin bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis 1990;142:24–28.CrossRefGoogle Scholar
  58. 58.
    Menzies RI, Vissandjee B, Rocher I, St. Germain Y. The booster effect in 2-step tuberculin testing among adults in Montreal. Ann Intern Med 1994;120:190–98.CrossRefGoogle Scholar
  59. 59.
    Friedland IR. The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. S Afr Med J 1990;77:387–89.PubMedGoogle Scholar
  60. 60.
    Wilson JM, Galbraith JD, Grzybowski S. Tuberculosis in Eskimo children. A comparison in children vaccinated with bacille Calmette-Guérin and non-vaccinated children. Am Rev Respir Dis 1973;108:559–64.PubMedGoogle Scholar
  61. 61.
    Shannon A, Kelly P, Lucey M, Cooney M, Corcoran P, Clancy L. Isoniazid resistant tuberculosis in a school outbreak: The protective effect of BCG. Eur Respir J 1991;4:778–82.PubMedGoogle Scholar
  62. 62.
    McMurray DN, Carlomagno MA, Mintzer CL, Tetzlaff CL. Mycobacterium bovis BCG vaccine fails to protect protein deficient guinea pigs against respiratory challenge with virulent Mycobacterium tuberculosis. Infect Immun 1985;50:555–59.PubMedPubMedCentralGoogle Scholar
  63. 63.
    McMurray DN, Mintzer CL, Tetzlaff CL, Carlomagno MA. Influence of dietary protein on the protective effect of BCG in guinea pigs. Tubercle 1986;67:31–39.CrossRefGoogle Scholar
  64. 64.
    Galbraith JD, Grzybowski S, Law CL, Rowe J. Tuberculosis in Indian children. CMAJ 1969;11:497–502.Google Scholar
  65. 65.
    Young TK. BCG vaccination among Canadian Indians and Inuit: The epidemiologic basis for policy decision. Can J Public Health 1985;76:124–29.PubMedGoogle Scholar
  66. 66.
    Bleicker MA, Grzybowski S, Styblo K, Sutherland I. Possibilities of omitting BCG vaccination on a random basis in countries where BCG is obligatory at birth. Bull IUAT 1970;44:61–62.Google Scholar

Copyright information

© The Canadian Public Health Association 2004

Authors and Affiliations

  • Richard Long
    • 1
    Email author
  • Denise Whittaker
    • 2
  • Krista Russell
    • 3
  • Dennis Kunimoto
    • 1
  • Robert Reid
    • 4
  • Anne Fanning
    • 1
  • Ewa Nobert
    • 1
  • Lyle Melenka
    • 1
  • Wadieh Yacoub
    • 3
  • Ravi Bhargava
    • 5
    • 6
  1. 1.Department of MedicineUniversity of AlbertaEdmontonCanada
  2. 2.Alberta Health and WellnessAlbertaCanada
  3. 3.First Nations and Inuit Health Branch, Health CanadaAlberta RegionCanada
  4. 4.The Group Health CooperativeSeattleUSA
  5. 5.Department of Radiology and Diagnostic ImagingUniversity of AlbertaCanada
  6. 6.Department of PediatricsUniversity of AlbertaCanada

Personalised recommendations